Cita APA

Sepúlveda, J. M., Vieito Villar, M., Hernández-Guerrero, T., Doger, B., Saavedra Gadea, O., Braña Garcia, I., & Moreno, V. (2020). Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.

Citación estilo Chicago

Sepúlveda, Juan Manuel, Maria Vieito Villar, T. Hernández-Guerrero, B. Doger, Omar Saavedra Gadea, Irene Braña Garcia, y Victor Moreno. Phase I Study of CC-90010, a Reversible, Oral BET Inhibitor in Patients With Advanced Solid Tumors and Relapsed/refractory Non-Hodgkin's Lymphoma. 2020.

Cita MLA

Sepúlveda, Juan Manuel, et al. Phase I Study of CC-90010, a Reversible, Oral BET Inhibitor in Patients With Advanced Solid Tumors and Relapsed/refractory Non-Hodgkin's Lymphoma. 2020.